




RealRate

PHARMACEUTICAL 2022

Dermata Therapeutics Inc.
Rank 371 of 475



RealRate

• Financial Strength Rankings using Artificial Intelligence

• www.realrate.ai



PHARMACEUTICAL 2022

Dermata Therapeutics Inc. Rank 371 of 475

The relative strengths and weaknesses of Dermata Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Dermata Therapeutics Inc. compared to the market average is the variable Expenses, increasing the Economic Capital Ratio by 337% points. The greatest weakness of Dermata Therapeutics Inc. is the variable Other Net Income, reducing the Economic Capital Ratio by 479% points.

The company's Economic Capital Ratio, given in the ranking table, is -319%, being 43% points below the market average of -276%.

Input Variable	Value in 1000 USD
Assets, Current	11,624
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	1,517
Liabilities, Non-Current	0
Other Assets	0
Other Compr. Net Income	0
Other Expenses	46
Other Liabilities	0
Other Net Income	-7,857
Property and Equipment	0
Research and Development	0
Revenues	0
Selling, General and Administrative Expense	0

Output Variable	Value in 1000 USD
Assets	11,624
Liabilities	1,517
Expenses	46
Stockholders Equity	10,107
Net Income	-7,902
Comprehensive Net Income	-7,902
Economic Capital Ratio	-319%

